Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Moharil, Z. Udwadia (Mumbai/Maharashtra, India). Treating extensively drug resistant tuberculosis (XDR-TB) in India. Eur Respir J 2008; 32: Suppl. 52, 2548

Member's Comments

No comment yet.

Related content which might interest you: Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis Source: Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018 Year: 2019 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: epidemiology, diagnosis and treatment Source: Annual Congress 2008 - Infection year in review Year: 2008 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Laboratory system to detect multidrug-resistant (MDR) and extensively drug-resistant (XDR) mycobacterium tuberculosis strains in clinical practice Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 564-574 Year: 2016 Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 A case of resistance beyond extensively drug-resistant tuberculosis in Japan Source: Eur Respir J 2013; 42: 872-873 Year: 2013 A case of resistance beyond extensively drug-resistant tuberculosis in Japan Source: Eur Respir J 2013; 42: 870-872 Year: 2013 Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009–2016 Source: Eur Respir J, 52 (1) 1800070; 10.1183/13993003.00070-2018 Year: 2018 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013